Ezetimibe Shortage: What Providers and Prescribers Need to Know in 2026

Ezetimibe remains one of the most commonly prescribed non-statin cholesterol agents in the United States, recommended by the ACC/AHA as a first add-on therapy when maximally tolerated statin therapy fails to achieve LDL targets. While ezetimibe is not currently on the FDA's national drug shortage list, clinicians in certain regions have reported patient difficulty in filling prescriptions — creating an operational challenge that warrants attention at the practice level.

Current Shortage Status: National vs. Local

As of 2026, the FDA CDER drug shortage database does not list ezetimibe 10 mg as a shortage drug. Generic ezetimibe is manufactured by a broad base of FDA-approved pharmaceutical companies — including Teva, Aurobindo, Mylan (Viatris), and Apotex — reducing the risk of a true national shortage.

However, localized supply disruptions have been observed at the retail level, driven by:

PBM formulary preference for specific generic manufacturers, causing inventory gaps when those manufacturers face delays

Increased demand from guideline-driven expansion of ezetimibe use in primary and secondary prevention

Independent pharmacy lean-inventory models that result in stock-outs between reorder cycles

Clinical Background: Why Ezetimibe Matters

Ezetimibe selectively inhibits the NPC1L1 transporter in the intestinal brush border, reducing cholesterol absorption by approximately 54% without affecting fat-soluble vitamin absorption. As monotherapy, it reduces LDL-C by 13-20%. Combined with a moderate-intensity statin, it provides an additional 21-27% LDL reduction — roughly equivalent to doubling the statin dose without the associated myopathy risk.

The landmark IMPROVE-IT trial demonstrated that ezetimibe plus simvastatin significantly reduced cardiovascular outcomes (composite of cardiovascular death, MI, UA hospitalization, revascularization, or stroke) compared with simvastatin alone in post-ACS patients (HR 0.936, p=0.016). These data cemented ezetimibe's role in secondary prevention guidelines.

Prescribing Considerations When Ezetimibe Is Unavailable

When a patient cannot access ezetimibe, consider the following tiered approach:

1. Facilitate pharmacy transfer or special order: Before switching therapy, consider directing patients to a pharmacy that has stock or asking them to call their pharmacy about a next-day order. Tools like medfinder can help patients locate pharmacies with stock without requiring a prescription change.

2. Increase statin intensity (if tolerated): If the patient was on ezetimibe plus a moderate-intensity statin, increasing the statin to maximum tolerated dose can partially compensate during a short gap in ezetimibe supply.

3. Bridge with bempedoic acid (Nexletol): For statin-intolerant patients dependent on ezetimibe monotherapy, bempedoic acid offers a complementary mechanism (ATP citrate lyase inhibition) with comparable LDL reduction (15-25%) and no muscle-related side effects. The fixed-dose combination Nexlizet (bempedoic acid + ezetimibe) is also an option if ezetimibe is later restored.

4. Consider PCSK9 inhibitors for high-risk patients: For post-ACS or HoFH patients at very high cardiovascular risk, a PCSK9 inhibitor (evolocumab, alirocumab) may be appropriate if ezetimibe will be unavailable for an extended period. Note that prior authorization is required and turnaround time may be several days.

Formulary and Prior Authorization Considerations

Generic ezetimibe is typically Tier 1-2 on most commercial and Medicare Part D formularies, with few prior authorization requirements. Documentation of a shortage-related access problem may help support PA appeals for alternatives like PCSK9 inhibitors or Nexlizet, which often require step therapy through statin and ezetimibe first.

When requesting a PA exception for a PCSK9 inhibitor due to ezetimibe unavailability, document the specific dates and pharmacies where ezetimibe was unavailable, and the clinical urgency based on the patient's LDL level and cardiovascular risk category.

Special Populations: When Continuity Is Critical

The following patient populations require particular vigilance around ezetimibe continuity:

Post-ACS patients: LDL targets <70 mg/dL (or <55 mg/dL for very high risk) per ACC/AHA guidelines. Gaps in ezetimibe therapy may delay achieving targets and increase recurrence risk.

HoFH patients: Ezetimibe is a cornerstone of HoFH therapy. These patients already have severely impaired LDL clearance and cannot tolerate prolonged gaps in therapy.

Statin-intolerant patients: Patients who depend on ezetimibe as their primary LDL-lowering agent have no easy fallback if supply is interrupted. Proactive planning for alternative sourcing is especially important for this group.

How Providers Can Help Patients Access Ezetimibe

Providers can direct patients to medfinder for providers — a service that calls pharmacies near the patient to find which ones currently have ezetimibe in stock. This avoids the need for a prescription change, prior authorization, or patient enrollment in a savings program, and is particularly efficient for practices that see multiple patients with access issues simultaneously.

See also: How to help your patients find ezetimibe in stock: a provider's guide.